Univest
Univest
  • Markets

Balaxi Pharmaceuticals Ltd. (BALAXI) Share Price Rise Streak: 2nd Straight Gain

  • November 18, 2026
  • Posted by: Kunal Singla
  • Category: News
No Comments
Balaxi Pharmaceuticals Ltd. Share Price Rise Streak
Balaxi Pharmaceuticals Ltd. (BALAXI) share price rose to Rs 28.9 today, up 9.18% from the previous close. Market cap was Rs 121.79 crore.

Balaxi Pharmaceuticals Ltd. Share Price is trading in its second straight session of gains at Rs 28.90, up 9.18%, with a market capitalisation of Rs 121.79 Cr. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established.

Balaxi Pharmaceuticals Ltd. Share Price Rise Streak has now reached 31.01% across two consecutive sessions, starting from Rs 22.06 on 17 November 2026. For readers tracking Balaxi Pharmaceuticals Ltd. Share Price Today, the streak matters because it shows a repeated higher-price pattern rather than a one-off move. The latest Univest figures also place the company in a smaller market-cap base, so the same percentage move has a visible effect on the share price. As of 18 November 2026 at 9:52:54 AM IST, the focus is on what the numbers show, not on any unverified trigger.

Table of Contents

Toggle
  • Balaxi Pharmaceuticals Ltd. Share Price Rise Streak: Consecutive Gain Analysis
  • What the Consecutive Gains Show
  • Balaxi Pharmaceuticals Ltd. (BALAXI) Fundamental Analysis
  • Sector and Industry Context
  • Peer Comparison
  • Why Investors Are Watching Balaxi Pharmaceuticals Ltd.
  • About Balaxi Pharmaceuticals Ltd.
  • Frequently Asked Questions
    • What is Balaxi Pharmaceuticals Ltd. Share Price today?
    • What does the Balaxi Pharmaceuticals Ltd. Share Price Rise Streak mean?
    • How did Balaxi Pharmaceuticals Ltd. Share Price move during the session?
    • What is Balaxi Pharmaceuticals Ltd. Share Price valuation now?
    • How does Balaxi Pharmaceuticals Ltd. compare with the Trading sector?
    • How does Balaxi Pharmaceuticals Ltd. compare with peers?
    • What are the key financial figures for Balaxi Pharmaceuticals Ltd. Share Price?
  • Track Balaxi Pharmaceuticals Ltd. Share Price on Univest

Balaxi Pharmaceuticals Ltd. Share Price Rise Streak: Consecutive Gain Analysis

Balaxi Pharmaceuticals Ltd. Share Price Rise Streak is therefore being read as a two-session pattern, not as a completed multi-day trend. That distinction matters for Balaxi Pharmaceuticals Ltd. Share Price analysis because a second straight session can look different from a single day’s gain when investors assess price, valuation and sector position. The next sections explain the session, the valuation base and how Balaxi Pharmaceuticals Ltd. Share Price stands against the Trading industry benchmark and peers.

Balaxi Pharmaceuticals Ltd. (BALAXI) rose to Rs 28.9 from the previous close of Rs 26.47, a move of Rs 2.43 or 9.18%. The stock opened at Rs 30, reached a high of Rs 30.9, recorded a low of Rs 27.8.

Balaxi Pharmaceuticals Ltd. Share Price Today shows a clear extension of the streak, with the latest traded price at Rs 28.90 versus the previous close of Rs 26.47. The move translates into a gain of Rs 2.43, or 9.18%, and the stock traded between Rs 27.80 and Rs 30.90 after opening at Rs 30.00. Within that range, the latest traded price sat in the lower half after earlier trading near the day’s upper zone.

For Balaxi Pharmaceuticals Ltd. Share Price Rise Streak readers, the key point is not only the size of the rise but also the fact that the stock has built this move over a second straight session. Balaxi Pharmaceuticals Ltd. Share Price Today therefore reflects both the current session’s price action and the cumulative streak move from Rs 22.06. The market capitalisation stands at Rs 121.79 Cr, which gives the move a defined base in the broader Indian Stock Market. This is a price action story first, and the valuation discussion follows from there.

What the Consecutive Gains Show

The second straight session is the most important feature in Balaxi Pharmaceuticals Ltd. Share Price Rise Streak. The cumulative move of 31.01% across two sessions is much larger than the latest day’s 9.18% rise, so the streak lens changes how the stock is read. Balaxi Pharmaceuticals Ltd. Share Price therefore needs to be viewed as a run of consecutive higher sessions rather than as an isolated intraday gain.

The streak also helps frame the starting point. The move began from Rs 22.06 on 17 November 2026 and reached Rs 28.90 in the latest session. That means Balaxi Pharmaceuticals Ltd. Share Price has already reset materially within two trading days, even though the current session alone does not establish a company-specific reason. According to latest Univest data, the price event is confirmed, but no company-specific catalyst is established. For readers, that makes Balaxi Pharmaceuticals Ltd. Share Price Rise Streak a useful case study in how quickly the market can reprice a low-priced stock over consecutive sessions.

Balaxi Pharmaceuticals Ltd. (BALAXI) Fundamental Analysis

Metric Value
Market Capitalisation Rs 121.79 crore
P/E Ratio 43.43x
P/B Ratio 0.57x
ROE 0.59%
ROCE 3.48%
EPS Rs 0.61
Book Value Per Share Rs 46.04
Dividend Yield 0%

Balaxi Pharmaceuticals Ltd. (BALAXI) fundamental metrics show P/E 43.43x, P/B 0.57x, ROE 0.59%, ROCE 3.48%. These figures provide context only and are not a buy or sell signal.

Balaxi Pharmaceuticals Ltd. has a market capitalisation of Rs 121.79 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 43.43x, P/B at 0.57x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 0.59% and ROCE of 3.48%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 0.61, book value per share of Rs 46.04, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 22.14x, median ROE of 4.18%, median ROCE of 6.06%. Taken together, they outline the fundamentals rather than a view on the stock.

Sector and Industry Context

Metric Value
Sector Trading
Industry Trading
Benchmark Scope same industry
Company P/E Ratio 43.43x
Benchmark Median P/E 22.14x
Benchmark Average P/E 94.81x
Benchmark P/E Range 0.1x to 4,681.8x
Company P/B Ratio 0.57x
Benchmark Median P/B 1.34x
Company ROE 0.59%
Benchmark Median ROE 4.18%
Company ROCE 3.48%
Benchmark Median ROCE 6.06%
Company Market Capitalisation Rs 121.79 crore
Benchmark Median Market Cap Rs 55.15 crore

Balaxi Pharmaceuticals Ltd. (BALAXI) operates in the Trading sector, within the Trading industry.

Balaxi Pharmaceuticals Ltd. (BALAXI) has a P/E ratio of 43.43x, which is above the benchmark median of 22.14x, a difference of +96.16%. On its own, the P/E gap is a valuation reference point, not a trading call.

Balaxi Pharmaceuticals Ltd. (BALAXI) has a ROE of 0.59%, which is below the benchmark median of 4.18%, a difference of -85.89%. Balaxi Pharmaceuticals Ltd. (BALAXI) has a ROCE of 3.48%, which is below the benchmark median of 6.06%, a difference of -42.57%.

Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.

Peer Comparison

Company Symbol Market Cap (Cr) P/E P/B ROE (%) ROCE (%)
Adani Enterprises Ltd. ADANIENT 3,60,090.21 64.71 3.79 15.07 13.3
ADITYA INFOTECH LIMITED CPPLUS 48,635.13 82.46 13.32 25.68 29.48
Aegis Logistics Ltd. AEGISLOG 43,071.21 34.62 6.4 20.71 19.76
Premier Energies Ltd. PREMIERENE 37,398.8 21.39 7.32 42.6 33.72
Redington Ltd. REDINGTON 26,638.96 14.46 2.49 13.6 18.96

Balaxi Pharmaceuticals Ltd. (BALAXI) has a P/E ratio of 43.43x compared with the displayed peer median of 34.62x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 0.59% compares with a peer median of 20.71% across the companies shown in the table. ROCE stood at 3.48% versus the displayed peer median of 19.76%, providing a capital-efficiency comparison. Balaxi Pharmaceuticals Ltd. (BALAXI) has a market capitalisation of Rs 121.79 crore. All 5 peers shown have a larger market capitalisation.

Why Investors Are Watching Balaxi Pharmaceuticals Ltd.

  • Balaxi Pharmaceuticals Ltd. Share Price is in a second straight session of gains, and the cumulative move across the streak is 31.01%.
  • The latest traded price of Rs 28.90 is above the previous close of Rs 26.47, with the session moving between Rs 27.80 and Rs 30.90.
  • Balaxi Pharmaceuticals Ltd. Share Price Rise Streak has lifted attention toward valuation, especially with P/E at 43.43 and P/B at 0.57.
  • The Trading sector comparison shows Balaxi Pharmaceuticals Ltd. Share Price above the sector median P/E, while ROE and ROCE remain below sector medians.
  • Balaxi Pharmaceuticals Ltd. Share Price is still backed by a market capitalisation of Rs 121.79 Cr, which keeps the move visible on a percentage basis.

About Balaxi Pharmaceuticals Ltd.

Balaxi Pharmaceuticals Ltd. operates in the Trading sector and the Trading industry. For Balaxi Pharmaceuticals Ltd. Share Price Rise Streak readers, the useful business context is that the company is being assessed within a trading-led benchmark rather than a manufacturing or pure pharma operating model in this dataset. That matters because Balaxi Pharmaceuticals Ltd. Share Price is being interpreted through valuation and market-cap lenses, not through a detailed operating breakdown here.

The company’s current figures show a market capitalisation of Rs 121.79 Cr, a P/E of 43.43, a P/B of 0.57, ROE of 0.59%, ROCE of 3.48%, EPS of Rs 0.61, book value of Rs 46.04 and dividend yield of 0.00%. In a streak article, the point is not to retell the entire corporate history. It is to give enough business context for Balaxi Pharmaceuticals Ltd. Share Price to be read alongside its valuation and sector positioning.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).

Frequently Asked Questions

What is Balaxi Pharmaceuticals Ltd. Share Price today?

Ans. Balaxi Pharmaceuticals Ltd. Share Price is trading at Rs 28.90 as of 18 November 2026 at 9:52:54 AM IST. It is up Rs 2.43, or 9.18%, versus the previous close of Rs 26.47.

What does the Balaxi Pharmaceuticals Ltd. Share Price Rise Streak mean?

Ans. Balaxi Pharmaceuticals Ltd. Share Price Rise Streak means the stock has risen in a second straight session. The cumulative move is 31.01% from Rs 22.06, so the focus is on the pattern across two sessions, not only today’s rise.

How did Balaxi Pharmaceuticals Ltd. Share Price move during the session?

Ans. Balaxi Pharmaceuticals Ltd. Share Price opened at Rs 30.00, touched a high of Rs 30.90 and a low of Rs 27.80, and last traded at Rs 28.90. That places the stock within a clear intraday range.

What is Balaxi Pharmaceuticals Ltd. Share Price valuation now?

Ans. Balaxi Pharmaceuticals Ltd. Share Price is paired with a P/E of 43.43 and a P/B of 0.57. The streak has lifted the price, while the earnings and book-value base remain unchanged across the run.

How does Balaxi Pharmaceuticals Ltd. compare with the Trading sector?

Ans. Balaxi Pharmaceuticals Ltd. Share Price has a P/E above the sector median of 22.14, while its P/B of 0.57 is below the sector median of 1.34. ROE and ROCE are also below the benchmark medians.

How does Balaxi Pharmaceuticals Ltd. compare with peers?

Ans. Balaxi Pharmaceuticals Ltd. Share Price has a smaller market capitalisation than Redington, Cello World and MMTC. Its P/E is higher than those three peers, while its P/B, ROE and ROCE are lower on the figures shown here.

What are the key financial figures for Balaxi Pharmaceuticals Ltd. Share Price?

Ans. Balaxi Pharmaceuticals Ltd. Share Price is backed by market capitalisation of Rs 121.79 Cr, EPS of Rs 0.61, book value of Rs 46.04, ROE of 0.59%, ROCE of 3.48% and dividend yield of 0.00%.

Track Balaxi Pharmaceuticals Ltd. Share Price on Univest

Use Balaxi Pharmaceuticals Ltd. (BALAXI) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.

Readers tracking Balaxi Pharmaceuticals Ltd. Share Price can use Univest to follow the latest traded price, valuation ratios, market capitalisation, 52-week levels and company insights in one place. Balaxi Pharmaceuticals Ltd. Share Price Rise Streak is best followed alongside the same fundamental and sector numbers used here, so that each new session can be read in context.



Author: Kunal Singla
Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.

Leave a Reply Cancel reply